Salk researcher named Damon Runyon Fellow

January 26, 2012

Salk researcher named Damon Runyon Fellow

Leading Cancer Research Foundation grants Fellowship award to top young scientist

January 26, 2012

LA JOLLA, CA—Lora B. Sweeney, a postdoctoral researcher at the Salk Institute for Biological Studies has been named a Damon Runyon Fellow.

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, selected Sweeney as one of only 18 recipients at its fall Fellowship Award Committee review. The prestigious $156,000 award is intended to encourage the nation’s most-promising young investigators to pursue careers in cancer research by providing them with independent funding to work on innovative projects.

Sweeney was sponsored by Christopher R. Kintner, professor of the Molecular Neurobiology Laboratory at the Salk Institute and Thomas M. Jessell, a Salk Non-Resident Fellow (NRF) and professor in the Department of Biochemistry and Molecular Biophysics of Columbia University in New York.

As a NRF, Jessell is part of an elite group of scientists nominated by the Salk President and faculty who serve as Salk investigators for renewable six-year terms, advising the institute on appointments, promotions and scientific programs.

Sweeney is using the frog as a model to study how neurons diversify in the spinal cord as limbs develop and a swimming tadpole becomes a hopping frog. Many different types of nerve cells, each with their own unique characteristics, make up the healthy nervous system. Understanding how a cell’s fate is specified will provide the basis for understanding how cancer reprograms a cell.

“I hope tracking the same course as evolution—from swimming to limb-based movement—in a single organism that we reveal new principles of neuron identity, organization and ultimately, function,” said Sweeney. “As one of the first scientists to work on the metamorphic frog, we are developing a new system. It is wonderful to have the support of Damon Runyon on this pioneering journey.”

Damon Runyon Cancer Research Foundation
To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today’s best young scientists with funding to pursue innovative research. The Foundation has gained worldwide prominence in cancer research by identifying outstanding researchers and physician-scientists. Eleven scientists supported by the Foundation have received the Nobel Prize, and others are heads of cancer centers and leaders of renowned research programs. Each of its award programs is extremely competitive, with less than 10% of applications funded. Since its founding in 1946, the Foundation has invested over $240 million and funded more than 3,300 young scientists. This year, it will commit approximately $10.8 million in new awards to brilliant young investigators.

100% of all donations to the Foundation are used to support scientific research. Its administrative and fundraising costs are paid from its Damon Runyon Broadway Tickets Service and endowment.

Acerca del Instituto Salk de Estudios Biológicos:
El Instituto Salk de Estudios Biológicos es una de las instituciones de investigación básica más destacadas del mundo, donde un cuerpo docente de prestigio internacional investiga cuestiones fundamentales de las ciencias de la vida en un entorno único, colaborativo y creativo. Centrados tanto en el descubrimiento como en la formación de las futuras generaciones de investigadores, los científicos del Salk realizan contribuciones revolucionarias a nuestra comprensión del cáncer, el envejecimiento, el Alzheimer, la diabetes y las enfermedades infecciosas mediante el estudio de la neurociencia, la genética, la biología celular y vegetal, y otras disciplinas relacionadas.

Los logros del cuerpo docente han sido reconocidos con numerosos galardones, entre los que se incluyen premios Nobel y la pertenencia a la Academia Nacional de Ciencias. Fundado en 1960 por el Dr. Jonas Salk, pionero en la vacuna contra la poliomielitis, el Instituto es una organización independiente sin fines de lucro y un hito arquitectónico.